Renaissance Capital logo

OPGN News

US IPO Weekly Recap: With 8 IPOs it's Bo-Time for Bojangles and no time for biotechs

BOJA

14 companies were scheduled to go public this week, including 10 health care deals. Only 8 IPOs got through, as 3 biotechs have been pushed back to next week, two companies postponed and one withdrew. however; IPO investors had plenty of options while the NASDAQ composite hit a 1-month low. This week's deals did include the year's largest IPO so far and the first restaurant chain...read more

HTG Molecular Diagnostics prices IPO at $14 midpoint and begins trading Wednesday

HTG Molecular Diagnostics, which markets a diagnostic platform for complex molecular profiling, raised $50 million by offering 3.6 million shares at $14, the midpoint of its $13 to $15 range. It priced and began trading on Wednesday. The week's other diagnostics IPO, OpGen (OPGN), priced and began trading on Tuesday. The company slashed its valuation by pricing 33% below...read more

OpGen prices IPO at $6, the midpoint of the downwardly revised range

OpGen, which provides genetic tests that identify multi-drug resistant bacterial infections, raised $17 million by offering 2.85 million units at $6, the midpoint of the downwardly revised range of $5.50 to $6.50. Each unit represents one common share and one warrant to purchase an additional share at 110% of the IPO price. OpGen plans to list on the NASDAQ under the symbol OPGN...read more

Week ahead: 14 IPOs planned for the week of May 4

BOJA

This could be the busiest 5-day stretch in the IPO market since the week of July 28, 2014, as 14 companies look to raise nearly $2 billion. However, last week's mediocre returns suggest that ...read more